Back to search

University of British Columbia

How do the jurisdictions of India, Canada and the United Kingdom interpret the inventive step requirement for follow-on pharmaceutical innovation?

Abstract

dc:description

This paper looks at the three jurisdictions of the United Kingdom, Canada and India to determine how each interpret the inventive step, for follow-on pharmaceutical innovation. An analysis of domestic statutes and case law, allows the stringency of approach to the inventive step in each jurisdiction to be determined on a comparative basis. The paper provides the comparison by utilising two differing benchmarks as a means to establish a lenient, versus a stringent perspective. The stringent perspective is established from UN recommendations whilst the lenient perspective is provided by a critical analysis of the recommendations by Christopher Holman et al. The first three chapters detail the approach taken by each jurisdiction respectively. This is achieved through extensive literature reviews and case law analysis. Through a comparison of a dosage patent, which was challenged before both the Federal Court of Appeal and the UK Supreme Court this paper reveals the similarity in approach between the UK and Canada’s inventive step inquiries. The comparative nature of this paper further establishes the stringency of application in India, through a step by step, comparative analysis of the inventive step inquiries. The potential consequences of the stringent approach in India and the comparatively lenient applications in Canada and the UK, are established through summaries of key debates in this area. This includes ethical debates such as the vital ‘innovation v accessibility balance’, the controversial ‘lifecycle management plans’ and Erooms law. In order for these key concerns to be adequately accounted for, unnecessarily strict standards for the inventive should not be applied. It is established that an emphasis on flexibility in approach to the inventive step inquiry, as is beginning to emerge in the United Kingdom, is an appropriate first step towards an inventive step inquiry which is capable of accounting for these crucial concerns.

Degree

thesis:*
Name thesis:degree_name
Master of Laws - LLM
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Law
Grantor dc:publisher
University of British Columbia
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Rainforth, George

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/73895

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Rainforth, George. How do the jurisdictions of India, Canada and the United Kingdom interpret the inventive step requirement for follow-on pharmaceutical innovation?. master's thesis, University of British Columbia, 2020. http://hdl.handle.net/2429/73895